A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors

Giuseppe Giaccone, Sabine C. Linn, Jan Welink, Giles Catimel, Hans Stieltjes, Wim J F Van Der Vijgh, Corien Eeltink, Jan B. Vermorken, Herbert M. Pinedo

Research output: Contribution to journalArticle

Abstract

Forty-two patients with advanced solid tumors were entered into a dose- finding study of the combination of doxorubicin with the cyclosporin analogue SDZ PSC 833 (PSC), given by oral route. Patients received PSC at escalating doses, ranging from 2.5 to 25 mg/kg/day, for 5 days, in doses given every 12 h. Doxorubicin was given by i.v. push on day 3 of PSC administration, 4 h after the morning dose of PSC. Pharmacokinetic analyses of PSC and doxorubicin were performed. A total of 38 patients received a combination of PSC and doxorubicin, and 27 received doxorubicin alone in the first course. The major toxicity of the combination was hematological and was significantly more severe than that with doxorubicin alone; severe myelosuppression was already observed at the first PSC dose level, which required doxorubicin dose reduction from 50 to 35 mg/m2. At all dose levels of PSC, up to 17.5 mg/kg/day, there were at least two patients with grade 3 or 4 hematological toxicity, which was manageable in less heavily pretreated patients. A further PSC dose escalation was performed to 25 mg/kg/day, together with doxorubicin, at a further reduced dose of 20 mg/m2. At this dose, central nervous system toxicity became the most relevant side effect. The increase of toxicity in the combined treatment was supported by a significant increase of the area under the plasma concentration-time curve to ∞ of doxorubicin (54%) and a 10-fold increase of the area under the plasma concentration-time curve to ∞ of doxorubicinol. The pharmacological interaction was not dependent on the plasma concentration of PSC. The total body clearance of doxorubicin decreased by 30%. PSC plasma concentrations of > 1 μM at the time of doxorubicin administration were, in general, found at a dose of 7.5 mg/kg/day or higher. One patient had a partial response. In conclusion, PSC plasma concentrations that can revert multidrug resistance in experimental models could be achieved in patients who have solid tumors and who are treated with doxorubicin. However, a marked pharmacological interaction was found between doxorubicin and PSC, which led to substantial increase in hematological toxicity and required marked reduction of the doxorubicin dose. Further study of PSC may be warranted, in association with the investigation of P- glycoprotein expression and concentration of drugs in the tumor tissues.

Original languageEnglish (US)
Pages (from-to)2005-2015
Number of pages11
JournalClinical Cancer Research
Volume3
Issue number11
StatePublished - Nov 1997
Externally publishedYes

Fingerprint

Multiple Drug Resistance
Doxorubicin
Pharmacokinetics
Neoplasms
valspodar
Pharmacology
P-Glycoprotein
Cyclosporine
Theoretical Models
Central Nervous System

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Giaccone, G., Linn, S. C., Welink, J., Catimel, G., Stieltjes, H., Van Der Vijgh, W. J. F., ... Pinedo, H. M. (1997). A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clinical Cancer Research, 3(11), 2005-2015.

A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. / Giaccone, Giuseppe; Linn, Sabine C.; Welink, Jan; Catimel, Giles; Stieltjes, Hans; Van Der Vijgh, Wim J F; Eeltink, Corien; Vermorken, Jan B.; Pinedo, Herbert M.

In: Clinical Cancer Research, Vol. 3, No. 11, 11.1997, p. 2005-2015.

Research output: Contribution to journalArticle

Giaccone, G, Linn, SC, Welink, J, Catimel, G, Stieltjes, H, Van Der Vijgh, WJF, Eeltink, C, Vermorken, JB & Pinedo, HM 1997, 'A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors', Clinical Cancer Research, vol. 3, no. 11, pp. 2005-2015.
Giaccone, Giuseppe ; Linn, Sabine C. ; Welink, Jan ; Catimel, Giles ; Stieltjes, Hans ; Van Der Vijgh, Wim J F ; Eeltink, Corien ; Vermorken, Jan B. ; Pinedo, Herbert M. / A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. In: Clinical Cancer Research. 1997 ; Vol. 3, No. 11. pp. 2005-2015.
@article{da95b94a595f4a5d88144df169056d96,
title = "A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors",
abstract = "Forty-two patients with advanced solid tumors were entered into a dose- finding study of the combination of doxorubicin with the cyclosporin analogue SDZ PSC 833 (PSC), given by oral route. Patients received PSC at escalating doses, ranging from 2.5 to 25 mg/kg/day, for 5 days, in doses given every 12 h. Doxorubicin was given by i.v. push on day 3 of PSC administration, 4 h after the morning dose of PSC. Pharmacokinetic analyses of PSC and doxorubicin were performed. A total of 38 patients received a combination of PSC and doxorubicin, and 27 received doxorubicin alone in the first course. The major toxicity of the combination was hematological and was significantly more severe than that with doxorubicin alone; severe myelosuppression was already observed at the first PSC dose level, which required doxorubicin dose reduction from 50 to 35 mg/m2. At all dose levels of PSC, up to 17.5 mg/kg/day, there were at least two patients with grade 3 or 4 hematological toxicity, which was manageable in less heavily pretreated patients. A further PSC dose escalation was performed to 25 mg/kg/day, together with doxorubicin, at a further reduced dose of 20 mg/m2. At this dose, central nervous system toxicity became the most relevant side effect. The increase of toxicity in the combined treatment was supported by a significant increase of the area under the plasma concentration-time curve to ∞ of doxorubicin (54{\%}) and a 10-fold increase of the area under the plasma concentration-time curve to ∞ of doxorubicinol. The pharmacological interaction was not dependent on the plasma concentration of PSC. The total body clearance of doxorubicin decreased by 30{\%}. PSC plasma concentrations of > 1 μM at the time of doxorubicin administration were, in general, found at a dose of 7.5 mg/kg/day or higher. One patient had a partial response. In conclusion, PSC plasma concentrations that can revert multidrug resistance in experimental models could be achieved in patients who have solid tumors and who are treated with doxorubicin. However, a marked pharmacological interaction was found between doxorubicin and PSC, which led to substantial increase in hematological toxicity and required marked reduction of the doxorubicin dose. Further study of PSC may be warranted, in association with the investigation of P- glycoprotein expression and concentration of drugs in the tumor tissues.",
author = "Giuseppe Giaccone and Linn, {Sabine C.} and Jan Welink and Giles Catimel and Hans Stieltjes and {Van Der Vijgh}, {Wim J F} and Corien Eeltink and Vermorken, {Jan B.} and Pinedo, {Herbert M.}",
year = "1997",
month = "11",
language = "English (US)",
volume = "3",
pages = "2005--2015",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors

AU - Giaccone, Giuseppe

AU - Linn, Sabine C.

AU - Welink, Jan

AU - Catimel, Giles

AU - Stieltjes, Hans

AU - Van Der Vijgh, Wim J F

AU - Eeltink, Corien

AU - Vermorken, Jan B.

AU - Pinedo, Herbert M.

PY - 1997/11

Y1 - 1997/11

N2 - Forty-two patients with advanced solid tumors were entered into a dose- finding study of the combination of doxorubicin with the cyclosporin analogue SDZ PSC 833 (PSC), given by oral route. Patients received PSC at escalating doses, ranging from 2.5 to 25 mg/kg/day, for 5 days, in doses given every 12 h. Doxorubicin was given by i.v. push on day 3 of PSC administration, 4 h after the morning dose of PSC. Pharmacokinetic analyses of PSC and doxorubicin were performed. A total of 38 patients received a combination of PSC and doxorubicin, and 27 received doxorubicin alone in the first course. The major toxicity of the combination was hematological and was significantly more severe than that with doxorubicin alone; severe myelosuppression was already observed at the first PSC dose level, which required doxorubicin dose reduction from 50 to 35 mg/m2. At all dose levels of PSC, up to 17.5 mg/kg/day, there were at least two patients with grade 3 or 4 hematological toxicity, which was manageable in less heavily pretreated patients. A further PSC dose escalation was performed to 25 mg/kg/day, together with doxorubicin, at a further reduced dose of 20 mg/m2. At this dose, central nervous system toxicity became the most relevant side effect. The increase of toxicity in the combined treatment was supported by a significant increase of the area under the plasma concentration-time curve to ∞ of doxorubicin (54%) and a 10-fold increase of the area under the plasma concentration-time curve to ∞ of doxorubicinol. The pharmacological interaction was not dependent on the plasma concentration of PSC. The total body clearance of doxorubicin decreased by 30%. PSC plasma concentrations of > 1 μM at the time of doxorubicin administration were, in general, found at a dose of 7.5 mg/kg/day or higher. One patient had a partial response. In conclusion, PSC plasma concentrations that can revert multidrug resistance in experimental models could be achieved in patients who have solid tumors and who are treated with doxorubicin. However, a marked pharmacological interaction was found between doxorubicin and PSC, which led to substantial increase in hematological toxicity and required marked reduction of the doxorubicin dose. Further study of PSC may be warranted, in association with the investigation of P- glycoprotein expression and concentration of drugs in the tumor tissues.

AB - Forty-two patients with advanced solid tumors were entered into a dose- finding study of the combination of doxorubicin with the cyclosporin analogue SDZ PSC 833 (PSC), given by oral route. Patients received PSC at escalating doses, ranging from 2.5 to 25 mg/kg/day, for 5 days, in doses given every 12 h. Doxorubicin was given by i.v. push on day 3 of PSC administration, 4 h after the morning dose of PSC. Pharmacokinetic analyses of PSC and doxorubicin were performed. A total of 38 patients received a combination of PSC and doxorubicin, and 27 received doxorubicin alone in the first course. The major toxicity of the combination was hematological and was significantly more severe than that with doxorubicin alone; severe myelosuppression was already observed at the first PSC dose level, which required doxorubicin dose reduction from 50 to 35 mg/m2. At all dose levels of PSC, up to 17.5 mg/kg/day, there were at least two patients with grade 3 or 4 hematological toxicity, which was manageable in less heavily pretreated patients. A further PSC dose escalation was performed to 25 mg/kg/day, together with doxorubicin, at a further reduced dose of 20 mg/m2. At this dose, central nervous system toxicity became the most relevant side effect. The increase of toxicity in the combined treatment was supported by a significant increase of the area under the plasma concentration-time curve to ∞ of doxorubicin (54%) and a 10-fold increase of the area under the plasma concentration-time curve to ∞ of doxorubicinol. The pharmacological interaction was not dependent on the plasma concentration of PSC. The total body clearance of doxorubicin decreased by 30%. PSC plasma concentrations of > 1 μM at the time of doxorubicin administration were, in general, found at a dose of 7.5 mg/kg/day or higher. One patient had a partial response. In conclusion, PSC plasma concentrations that can revert multidrug resistance in experimental models could be achieved in patients who have solid tumors and who are treated with doxorubicin. However, a marked pharmacological interaction was found between doxorubicin and PSC, which led to substantial increase in hematological toxicity and required marked reduction of the doxorubicin dose. Further study of PSC may be warranted, in association with the investigation of P- glycoprotein expression and concentration of drugs in the tumor tissues.

UR - http://www.scopus.com/inward/record.url?scp=0030666026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030666026&partnerID=8YFLogxK

M3 - Article

C2 - 9815591

AN - SCOPUS:0030666026

VL - 3

SP - 2005

EP - 2015

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 11

ER -